Makers Laboratories Ltd

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 1 April 2026, reflecting a marked improvement in its quarterly financial performance and a reassessment of its valuation and technical outlook. Despite lingering concerns over long-term fundamentals, the company’s recent results and market behaviour have prompted analysts to revise their stance, signalling cautious optimism for investors.

The 50-day moving average for Makers Laboratories Ltd has crossed above the 200-day moving average, signalling a golden cross on 25 Mar 2026. Yet, this technical milestone arrives amid a complex backdrop of conflicting momentum indicators and a micro-cap status that tempers the signal’s reliability.

Makers Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 23 March 2026, driven primarily by a shift in technical indicators despite persistent challenges in valuation and long-term financial fundamentals. The micro-cap pharmaceutical company’s recent quarterly performance showed promising signs, yet its overall financial health and valuation metrics continue to weigh on investor sentiment.

Makers Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 16 Mar 2026, reflecting a deteriorating outlook driven primarily by weakening technical indicators, expensive valuation metrics, and disappointing long-term financial trends despite recent positive quarterly results.

Makers Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 Mar 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The company’s stock price has gained nearly 5% in a single day, reflecting renewed market interest amid mixed signals from financial performance and valuation metrics.

Makers Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s valuation, long-term financial trends, and technical signals have collectively triggered a reassessment of its investment appeal.

Makers Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by improved technical indicators and recent positive quarterly financial results. However, the company continues to face challenges in valuation and long-term fundamental strength, prompting a cautious stance despite short-term momentum gains.

Makers Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 17 Feb 2026, reflecting a deterioration in its technical outlook, valuation metrics, and long-term financial trends. Despite some positive quarterly results, the company’s overall fundamentals and market performance have raised concerns, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Makers Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell following a marked improvement in its financial performance and technical indicators. Despite lingering concerns over long-term fundamentals and valuation, the recent quarterly results and market momentum have prompted a reassessment of the company’s outlook.

Makers Laboratories Ltd has demonstrated a notable turnaround in its quarterly financial performance for December 2025, registering its highest-ever net sales and profitability metrics despite a challenging nine-month period marked by significant profit contraction. The company’s recent financial trend has shifted from flat to positive, signalling potential recovery in the Pharmaceuticals & Biotechnology sector.

Makers Laboratories Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹85.56 crores, reported a consolidated net profit of ₹0.94 crores for Q3 FY26 (October-December 2025), marking a dramatic turnaround from a loss of ₹0.30 crores in the year-ago quarter. However, the seemingly impressive quarterly performance conceals troubling underlying trends that raise serious questions about the sustainability of this recovery.

Makers Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Makers Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 September 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Makers Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Makers Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 September 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 07 January 2026, providing investors with the latest insights into the company’s performance and outlook.